The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
TBCRC 048 (olaparib expanded) expansion cohorts: Phase 2 study of olaparib monotherapy in patients (pts) with metastatic breast cancer (MBC) with germline (g) mutations in PALB2 or somatic (s) mutations in BRCA1 or BRCA2.
 
Nadine M. Tung
Consulting or Advisory Role - AstraZeneca; GlaxoSmithKline
Research Funding - AstraZeneca (Inst)
 
Mark E. Robson
Consulting or Advisory Role - Change HealthCare
Research Funding - Artios (Inst); AstraZeneca (Inst); Merck (Inst); Pfizer (Inst); Zenith Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - AstraZeneca
Other Relationship - AstraZeneca; Clinical Care Options; Clinical Education Alliance; MJH Healthcare Holdings, LLC; MyMedEd; Pfizer; Physicans' Education Resource; Research to Practice
(OPTIONAL) Uncompensated Relationships - Artios; GlaxoSmithKline; Merck; Pfizer; Tempus; Zenith Pharmaceuticals
 
Rita Nanda
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo/Astra Zeneca; Exact Sciences; GE Healthcare; Gilead Sciences; Guardant Health; Merck; Moderna Therapeutics; Novartis; Sanofi; Seagen; Stemline Therapeutics
Research Funding - Arvinas (Inst); AstraZeneca (Inst); Celgene (Inst); Corcept Therapeutics (Inst); Genentech/Roche (Inst); Immunomedics (Inst); Merck (Inst); OBI Pharma (Inst); Odonate Therapeutics (Inst); OncoSec (Inst); Pfizer (Inst); Relay Therapeutics (Inst); Seagen (Inst); Sun Pharma (Inst); Taiho Oncology (Inst)
Other Relationship - G1 Therapeutics
 
Tianyu Li
No Relationships to Disclose
 
Shaveta Vinayak
Research Funding - Pfizer (Inst); Puma Biotechnology (Inst); Seagen (Inst)
 
Payal Deepak Shah
Stock and Other Ownership Interests - Amgen; Johnson & Johnson; Johnson & Johnson (I); Lilly; Merck (I); Moderna Therapeutics; Novartis (I); Novo Nordisk; Novo Nordisk (I); Pfizer (I)
Consulting or Advisory Role - Daiichi Sankyo; Gilead Sciences
Research Funding - AstraZeneca (Inst); Zenith Epigenetics (Inst)
 
Katia Khoury
No Relationships to Disclose
 
Gretchen Genevieve Kimmick
Honoraria - Research to Practice
Consulting or Advisory Role - bioTheranostics; Immunomedics; Novartis
Research Funding - Novartis (Inst); Pfizer (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - Royalties for CardioOncology textbook from Springer.; Royalties from Springer for textbook "Common Issues in Breast Cancer Survivors: A Practical Guide to Evaluation and Management."; UpToDate Royalties
 
Cesar Augusto Santa-Maria
Consulting or Advisory Role - Abbvie; Athenex; Bristol-Myers Squibb; Calibr; Genomic Health; Halozyme; Merck; Pfizer; Pfizer; Polyphor; Seagen
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Celldex (Inst); Genentech (Inst); Medimmune (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Pfizer (Inst); Tesaro (Inst)
 
Adam Brufsky
Consulting or Advisory Role - Agendia; Daiichi Sankyo/Lilly; Eisai; Genentech/Roche; General Electric; Gilead Sciences; Lilly; Merck; Michael J. Hennessy Associates; Myriad Pharmaceuticals; Novartis; Onc Live; Pfizer; Puma Biotechnology; Seagen
Research Funding - AstraZeneca/Daiichi Sankyo (Inst); Gilead Sciences (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Puma Biotechnology (Inst); Roche/Genentech (Inst)
Expert Testimony - Pfizer
 
Michelle DeMeo
No Relationships to Disclose
 
Joao Pedro Vieira
No Relationships to Disclose
 
Lisa A. Carey
Research Funding - AstraZeneca (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Lilly (Inst); NanoString Technologies (Inst); Novartis (Inst); Seagen (Inst); Veracyte (Inst)
(OPTIONAL) Uncompensated Relationships - Genentech/Roche (Inst); GlaxoSmithKline (Inst); Lilly; Novartis (Inst); SeaGen
 
Gerburg M. Wulf
Stock and Other Ownership Interests - Selecta Biosciences (I)
Research Funding - Genentech (Inst); GlaxoSmithKline (Inst); Merck; Seagen (Inst)
Patents, Royalties, Other Intellectual Property - Pin1 as a marker for abnormal cell growth Patent number: 8129131; Pin1 inhibitors (Inst)
 
Susan M. Domchek
Honoraria - AstraZeneca; GlaxoSmithKline
Research Funding - AstraZeneca (Inst); Clovis Oncology (Inst)
 
Ian E. Krop
Employment - PureTech (I)
Leadership - PureTech (I)
Stock and Other Ownership Interests - PureTech (I)
Honoraria - AstraZeneca; Daiichi Sankyo
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; Genentech/Roche; Merck; Novartis; Seagen
Research Funding - Genentech (Inst); Macrogenics (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - anti-murine CD19 monoclonal antibody licensed to PharMingen
 
Antonio C. Wolff
Patents, Royalties, Other Intellectual Property - Antonio Wolff has been named as inventor on one or more issued patents or pending patent applications relating to methylation in breast cancer, and has assigned his rights to JHU, and participates in a royalty sharing agreement with JHU.
 
Eric P. Winer
Research Funding - Genentech (Inst)
 
Judy Ellen Garber
Consulting or Advisory Role - Belharra Therapeutics, Inc. (I); Earli, Inc.; Earli, Inc.; Earli, Inc.; Earli, Inc.; GV20 Therapeutics (I); Kronos Bio (I); Novartis (I)
Research Funding - Ambry Genetics; Amgen; Amgen; Amgen; Amgen; InVitae; Novartis (I)
Other Relationship - AACR; Adrienne Helis Malvin Medical Research Foundation (I); Breast Cancer Research Foundation; Diana Helis Henry Medical Foundation (I); Facing our Risk of Cancer Empowered; James P. Wilmot Foundation; James P. Wilmot Foundation; James P. Wilmot Foundation; James P. Wilmot Foundation; James P. Wilmot Foundation; James P. Wilmot Foundation; James P. Wilmot Foundation; James P. Wilmot Foundation; James P. Wilmot Foundation; James P. Wilmot Foundation (I)